No Data
No Data
No Data
No Data
No Data
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
IRVINE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing
GlobeNewswireApr 26 08:00 ET
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination With Pembrolizumab at ASCO 2024
IRVINE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing
GlobeNewswireApr 24 10:00 ET
Buy Rating Affirmed for CG Oncology Amidst Bladder Cancer Treatment Landscape and BCG Shortage
TipRanksApr 23 08:25 ET
Buy Rating Affirmed for CG Oncology on Strong Clinical Data and Market Potential
TipRanksApr 4 06:15 ET
Express News | HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target
Moomoo 24/7Apr 4 06:11 ET
Buy Rating Justified by CG Oncology's Strong Clinical Trial Results and Promising Cretosimogene Therapy
TipRanksApr 1 07:36 ET
No Data
No Data